These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36283491)

  • 1. Novel drug delivery systems for the management of dry eye.
    Nagai N; Otake H
    Adv Drug Deliv Rev; 2022 Dec; 191():114582. PubMed ID: 36283491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress of nanomedicine in managing dry eye disease.
    Lv Z; Li S; Zeng G; Yao K; Han H
    Adv Ophthalmol Pract Res; 2024; 4(1):23-31. PubMed ID: 38356795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Nano-ophthalmology in Treating Dry Eye Disease.
    Natesan S; Boddu SHS; Krishnaswami V; Shahwan M
    Pharm Nanotechnol; 2020; 8(4):258-289. PubMed ID: 32600244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in drug treatments for dry eye disease.
    Coco G; Ambrosini G; Poletti S; Meliante LA; Taloni A; Scorcia V; Giannaccare G
    Expert Opin Pharmacother; 2023; 24(18):2059-2079. PubMed ID: 37804227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage.
    Xia Y; Zhang Y; Du Y; Wang Z; Cheng L; Du Z
    J Nanobiotechnology; 2024 May; 22(1):233. PubMed ID: 38725011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis.
    Gulati S; Jain S
    Handb Exp Pharmacol; 2017; 242():97-118. PubMed ID: 27913889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current trends in pharmaceutical treatment of dry eye disease: A review.
    Mohamed HB; Abd El-Hamid BN; Fathalla D; Fouad EA
    Eur J Pharm Sci; 2022 Aug; 175():106206. PubMed ID: 35568107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
    Nichols KK; Evans DG; Karpecki PM
    Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucin-targeting-aptamer functionalized liposomes for delivery of cyclosporin A for dry eye diseases.
    Wong KY; Liu Y; Zhou L; Wong MS; Liu J
    J Mater Chem B; 2023 May; 11(21):4684-4694. PubMed ID: 37161679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on dry eye disease molecular treatment: advances in drug pipelines.
    Colligris B; Crooke A; Huete-Toral F; Pintor J
    Expert Opin Pharmacother; 2014 Jul; 15(10):1371-90. PubMed ID: 24773445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.
    Labetoulle M; Benitez-Del-Castillo JM; Barabino S; Herrero Vanrell R; Daull P; Garrigue JS; Rolando M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomaterials for dry eye disease treatment: Current overview and future perspectives.
    Thacker M; Singh V; Basu S; Singh S
    Exp Eye Res; 2023 Jan; 226():109339. PubMed ID: 36470431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease].
    Pleyer U; Geerling G; Schrader S; Jacobi C; Kimmich F; Messmer E
    Klin Monbl Augenheilkd; 2020 May; 237(5):655-668. PubMed ID: 32434249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating primary dry eye disease from ocular neuropathic pain: implications for symptom management.
    Forristal MT; Stephenson KAJ
    Clin Exp Optom; 2023 Aug; 106(6):605-611. PubMed ID: 36004515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for 24-hour management of dry eye disease: A review.
    Guillon M; Shah S
    Cont Lens Anterior Eye; 2019 Apr; 42(2):147-154. PubMed ID: 30497903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management Strategies for Evaporative Dry Eye Disease and Future Perspective.
    Rolando M; Merayo-Lloves J
    Curr Eye Res; 2022 Jun; 47(6):813-823. PubMed ID: 35521685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing trends in the treatment of dry-eye disease.
    Dogru M; Nakamura M; Shimazaki J; Tsubota K
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1581-601. PubMed ID: 24088227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of artificial tears on dynamic optical quality in patients with dry eye disease.
    Wei Z; Su Y; Su G; Baudouin C; Labbé A; Liang Q
    BMC Ophthalmol; 2022 Feb; 22(1):64. PubMed ID: 35144571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.